t
Hutchmed (China) Limited announced on September 24, 2026, that new and updated clinical data from its compounds will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, from October 23-27, 2026. This includes results from two positive Phase III studies, SAFFRON and SANOVO, evaluating the savolitinib and osimertinib combination, which reported high-level results on August 17, 2026, and August 31, 2026, respectively, and are scheduled for oral presentations.
Press Release
Hong Kong, Shanghai & Florham Park, NJ — Thursday, September 24, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place on October 23-27, 2026, in Madrid, Spain.
Notably, results from two positive Phase III studies evaluating the savolitinib and osimertinib combination have been selected for oral presentations. Results from the global SAFFRON study will be featured in the Presidential Symposium session, while results from the SANOVO study in China will be presented in a Proffered Paper session, both highlighting important new clinical data. Having two Phase III studies featured as late-breaking abstracts underscores the potential of this all-oral, chemo-free combination to deliver meaningful advancements for patients with non-small cell lung cancer (“NSCLC”).
The SAFFRON Global Phase III Study has been selected for a Presidential Symposium oral presentation. The study evaluated the combination in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC with MET overexpression or amplification following disease progression on osimertinib. The trial reported positive high-level results on August 17, 2026, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (“PFS”) and overall survival (“OS”) compared to doublet platinum-based chemotherapy.
The SANOVO China Phase III Study has been selected for a Proffered Paper oral presentation. The study evaluated the combination in previously untreated patients with locally advanced or metastatic NSCLC harboring activating EGFR mutations and MET overexpression. The trial reported positive high-level results on August 31, 2026, demonstrating a statistically significant and clinically meaningful improvement in PFS and a clinically meaningful benefit in OS versus osimertinib monotherapy.
Details of the presentations are as follows:
|
Abstract title |
Presenter / Lead author |
Presentation details |
|
|
|
|
|
Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results |
Shun Lu |
LBA6 Presidential Symposium II Alicante Auditorium - Hall 6 Sunday, October 25, 2026 16:30 - 18:15 CEST |
|
Savolitinib or Placebo Combined with Osimertinib in Treatment-Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results from the Phase 3 SANOVO Study |
Yi-Long Wu |
LBA69 Proffered paper 2: NSCLC, metastatic Alicante Auditorium - Hall 6 Monday, October 26, 2026 08:30 - 10:00 CEST |
|
Updated results from a fruquintinib Expanded Access Program for patients with previously treated metastatic colorectal cancer |
Stefan Kasper |
848P Poster Session: Colon cancer |
|
Association between dose adjustment and treatment outcomes in patients with advanced renal cell carcinoma receiving fruquintinib plus sintilimab: A post-hoc analysis of the FRUSICA‑2 trial |
Yuanyuan Qu |
3655eP E-poster Session: Renal cancer |
|
Efficacy of fruquintinib plus sintilimab in special populations with advanced renal cell carcinoma: A subgroup analysis of FRUSICA‑2 study |
Kaiwei Yang |
3667eP E-poster Session: Renal cancer |
|
Final phase 2 analysis of surufatinib plus camrelizumab, nab‑paclitaxel and gemcitabine in first‑line metastatic pancreatic cancer |
Shukui Qin |
3156P Poster Session: Pancreatic cancer |
|
|
|
|
|
Fruquintinib plus capecitabine maintenance after first-line anti‑EGFR antibody plus chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer: A phase Ib/II study |
Lin Yang/ Letian Zhang |
877eP E-poster Session: Colon cancer |
|
Real-world effectiveness and safety of fruquintinib in patients with metastatic colorectal cancer in Spain: The FrESP study |
Ana Fernandez Montes |
880eP E-poster Session: Colon cancer |
|
CONCEPT (COmbinatioN of CEtuximab Plus fruquintinib Treatment ± immunotherapy): A multicenter, randomized, open-label phase II trial in first-line pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer |
Kefeng Ding |
890eP E-poster Session: Colon cancer |
|
A real-world study of low-dose fruquintinib combined with trifluridine/tipiracil hydrochloride (TAS-102) in the third‑line and beyond treatment of metastatic colorectal cancer |
Yuehong Cui/ Li Liang |
903eP E-poster Session: Colon cancer |
|
Real-world outcomes with fruquintinib in heavily pretreated metastatic colorectal cancer: Impact of patient and disease characteristics |
Maria Maddalena |
964eP E-poster Session: Colon cancer |
|
A phase II, open-label, randomized study of doublet chemotherapy (FOLFOX or FOLFIRI) plus fruquintinib compared with doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab in second line setting for a metastatic colorectal cancer: ULYSSE- FFCD2406 - PRODIGE115 (trials in progress) |
Jean Marc Phelip |
991eTiP E-poster Session: Colon cancer |
|
Phase II study of fruquintinib plus utidelone in platinum‑resistant recurrent ovarian cancer (FRUTD Trial) |
Zheng Feng |
1283P Poster Session: Gynaecological cancers |
|
Fruquintinib plus eribulin in patients with metastatic HR+, HER2‑breast cancer after progression on endocrine therapy plus CDK4/6 inhibitor: Updated results from a phase II study |
Yuan Yuan |
1896eP E-poster Session: HR+ breast cancer |
|
Fruquintinib plus sintilimab and XELOX as first‑line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: A single‑arm, open‑label, multicenter phase II study |
Hua Wang |
2980eP E-poster Session: Oesophagogastric cancer |
|
Fruquintinib plus cadonilimab and S-1 in previously treated unresectable locally advanced or metastatic esophageal squamous cell carcinoma: preliminary efficacy and safety results from a phase Ib/II study |
Huiyan Luo |
2981eP E-poster Session: Oesophagogastric cancer |
|
Nanoliposomal irinotecan (nal‑IRI) combined with fruquintinib as second-line treatment for advanced gastric cancer: A single‑arm, open‑label, dose-escalation and expansion phase I/II trial |
Jieer Ying/ Qi Xu |
2986eP E-poster Session: Oesophagogastric cancer |
|
FRUQUITAS trial: ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro‑oesophageal adenocarcinoma |
David Tougeron (Poitiers, France) |
3079eTiP E-poster Session: Oesophagogastric cancer |
|
CHOICE III: short-course preoperative radiotherapy followed by fruquintinib plus anti–PD‑1 antibody (serplulimab) for neoadjuvant treatment of pMMR/MSS mid‑to‑low locally advanced rectal cancer: A single‑arm, single‑center, prospective phase II study |
Wei Zhang |
3582eTiP E-poster Session: Rectal and anal cancer |
|
First-line fruquintinib plus serplulimab for metastatic non‑clear cell renal cell carcinoma: Updated results from the phase II FRONTIER study |
Jiwei Huang |
3614P |
|
Latest efficacy and safety analysis of surufatinib combined with EP regimen and serplulimab as first-line treatment for extrapulmonary neuroendocrine carcinoma |
Tao Zhang/ Zhenyu Lin |
2394RO Rapid Oral Session: NETs and endocrine tumours Pamplona Auditorium - Hall 5 Friday, October 23, 2026 16:15 - 17:45 CEST |
|
Surufatinib combined with toripalimab and nab‑paclitaxel/ gemcitabine chemotherapy as first‑line treatment for advanced pancreatobiliary-type ampullary carcinoma: A prospective phase II Clinical Trial |
Juan Du |
507eP E-poster Session: Biliary tract cancer, incl. cholangiocarcinoma |
|
Efficacy and safety of surufatinib in combination with CAPTEM in advanced G2/G3 Neuroendocrine Tumors: Results from a single‑arm, phase II Trial |
Wei Wang |
2403P Poster Session: Neuroendocrine tumours |
|
Surufatinib plus S‑1/temozolomide as first-line therapy in MGMT‑low advanced pancreatic neuroendocrine tumours (SUSTEM‑p): An open‑label, single‑centre phase Ib/II trial |
Yihebali Chi |
2411P Poster Session: Neuroendocrine tumours |
|
Updated results of a prospective, open‑label study of surufatinib plus CAPTEM as conversion therapy for unresectable pancreatic neuroendocrine tumors |
Ziyao Wang |
2412P Poster Session: Neuroendocrine tumours |
|
Matching‑adjusted indirect comparison of surufatinib versus high‑dose OCT‑LAR in patients with advanced GEP‑NETs who progressed on prior SSA Therapy |
Jianming Xu |
2415P Poster Session: Neuroendocrine tumours |
|
Surufatinib combined with octreotide LAR for the treatment of G1/G2 GEP‑NETs: A single‑arm, prospective, open‑label phase II study |
Xiaofeng Sun |
2439eP E-poster Session: Neuroendocrine tumours |
|
Six weeks of induction gemcitabine plus nab paclitaxel (AG) followed by sequential surufatinib plus AG or AG alone as first line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): A single center, two cohort, phase II study |
Jin Xu/ Jialin Li |
3168P Poster Session: Pancreatic cancer |
|
A phase Ib/II study of radiotherapy combined with surufatinib and sintilimab for localized high‑risk limb and trunk soft tissue sarcomas: A prospective single‑center trial |
Yan Wang |
3739P Poster Session: Sarcoma |
|
Surufatinib plus serplulimab, etoposide, and carboplatin as first‑line treatment for extensive-stage small cell lung cancer (ES‑SCLC): Updated results from a single‑arm, phase Ia/Ib trial |
Haipeng Xu/ Longfeng Zhang |
3831P Poster Session: Small cell lung cancer |
Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (“VEGFR”) -1, ‑2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®.
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS®.
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA®. HUTCHMED currently retains all rights to surufatinib worldwide.
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, surufatinib and savolitinib, the further clinical development for fruquintinib, surufatinib and savolitinib, its expectations as to whether any studies on fruquintinib, surufatinib and savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, surufatinib and savolitinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, surufatinib and savolitinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab and toripalimab as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
Investor Enquiries |
+852 2121 8200 / [email protected] |
|
|
|
Media Enquiries |
|
|
FTI Consulting – |
+44 20 3727 1030 / [email protected] |
|
Ben Atwell / Tim Stamper |
+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) |
|
Brunswick – Zhou Yi |
+852 9783 6894 (Mobile) / [email protected] |
|
|
|
Panmure Liberum |
Nominated Advisor and Joint Broker |
|
Atholl Tweedie / Emma Earl / Rupert Dearden |
+44 20 7886 2500 |
|
|
|
Cavendish |
Joint Broker |
|
Geoff Nash / Nigel Birks |
+44 20 7220 0500 |
|
|
|
Deutsche Numis |
Joint Broker |
|
Duncan Monteith / Ramin Naji |
+44 20 7545 8000 |